Pending FDA decision, the Viaskin Peanut patch would be considered for lengthier benefit studies.
Though DBV Technologies is in the process of facilitating research which would aid its goal toward regulatory approval for its novel epicutaneous immunotherapy (EPIT) Viaskin Peanut patch, for pediatric peanut allergy, the company has made enough progress in assessment of its unique treatment that big-picture questions surrounding its real-world use are warranted.
As Pharis Mohideen, MD, MS, DBV chief medical officer, told HCPLive®, the reality is that any regulated food allergy immunotherapy would serve some—not all—patients. With the average diagnosed patient being a child, the choice of treatment is atypical fom the standard patient-physician deliberation.
Some may choose an EPIT, or oral option—or no immunotherapy at all.
“It’s such an individualized, family decision,” Mohideen said. “I think there’s room for multiple therapies in the landscape. That’s basically what people want.”
In the second segment of his interview with HCPLive, Mohideen highlighted DBV’s commitment to long-term assessments into the Viaskin patch, beginning to understand its sustained responsiveness and lifestyle management roles beyond just a few months.
These are all difficult questions to answer for a growing patient population, but it helps to be answering them with such a novel product.
“The beauty of Viaskin Peanut is it’s a platform,” he explained. “We can use it in different ways and in different settings.”